CpG-induced antitumor immunity requires IL-12 in expansion of effector cells and down-regulation of PD-1

Peng Yin, Xin Liu, Aaron Mansfield, Susan M. Harrington, Yinghua Li, Yiyi Yan, Haidong M Dong

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

CpG oligodeoxynucleotides, as a ligand of toll-like receptor (TLR)-9, have demonstrated promising antitumor effects in some clinical trials; however, its toxicity and low efficacy as a systemic therapy has limited its therapeutic applications. In order to improve its therapeutic efficacy, we investigated the mechanisms of CpGinduced antitumor immunity in the context of CD8+ T cell responses. We show that IL-12 is required for the expansion of IFN-γ producing tumor-reactive CD8+ T cells capable of rejecting tumors. In addition, CpGs reduced PD-1 expression by effector CD8+ T cells via the IL-12 pathway. The combination of CpG and PD-1 blockade show a synergistic effect in generation of systemic antitumor immunity. Our studies define a critical role of IL-12 in CpG-induced antitumor immunity and provide a rationale for combined therapy with TLR agonists and immune checkpoint blockade in cancer treatment.

Original languageEnglish (US)
Pages (from-to)70223-70231
Number of pages9
JournalOncotarget
Volume7
Issue number43
DOIs
StatePublished - 2016

Fingerprint

Interleukin-12
Immunity
Down-Regulation
T-Lymphocytes
Toll-Like Receptor 9
Cohort Effect
Neoplasms
Oligodeoxyribonucleotides
Toll-Like Receptors
Therapeutics
Clinical Trials
Ligands

Keywords

  • CpG ODN
  • IL-12
  • Immune checkpoints
  • PD-1
  • Tumor immunotherapy

ASJC Scopus subject areas

  • Oncology

Cite this

CpG-induced antitumor immunity requires IL-12 in expansion of effector cells and down-regulation of PD-1. / Yin, Peng; Liu, Xin; Mansfield, Aaron; Harrington, Susan M.; Li, Yinghua; Yan, Yiyi; Dong, Haidong M.

In: Oncotarget, Vol. 7, No. 43, 2016, p. 70223-70231.

Research output: Contribution to journalArticle

@article{9b70ecb133a540c8b31fd6d369e40efa,
title = "CpG-induced antitumor immunity requires IL-12 in expansion of effector cells and down-regulation of PD-1",
abstract = "CpG oligodeoxynucleotides, as a ligand of toll-like receptor (TLR)-9, have demonstrated promising antitumor effects in some clinical trials; however, its toxicity and low efficacy as a systemic therapy has limited its therapeutic applications. In order to improve its therapeutic efficacy, we investigated the mechanisms of CpGinduced antitumor immunity in the context of CD8+ T cell responses. We show that IL-12 is required for the expansion of IFN-γ producing tumor-reactive CD8+ T cells capable of rejecting tumors. In addition, CpGs reduced PD-1 expression by effector CD8+ T cells via the IL-12 pathway. The combination of CpG and PD-1 blockade show a synergistic effect in generation of systemic antitumor immunity. Our studies define a critical role of IL-12 in CpG-induced antitumor immunity and provide a rationale for combined therapy with TLR agonists and immune checkpoint blockade in cancer treatment.",
keywords = "CpG ODN, IL-12, Immune checkpoints, PD-1, Tumor immunotherapy",
author = "Peng Yin and Xin Liu and Aaron Mansfield and Harrington, {Susan M.} and Yinghua Li and Yiyi Yan and Dong, {Haidong M}",
year = "2016",
doi = "10.18632/oncotarget.11833",
language = "English (US)",
volume = "7",
pages = "70223--70231",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "43",

}

TY - JOUR

T1 - CpG-induced antitumor immunity requires IL-12 in expansion of effector cells and down-regulation of PD-1

AU - Yin, Peng

AU - Liu, Xin

AU - Mansfield, Aaron

AU - Harrington, Susan M.

AU - Li, Yinghua

AU - Yan, Yiyi

AU - Dong, Haidong M

PY - 2016

Y1 - 2016

N2 - CpG oligodeoxynucleotides, as a ligand of toll-like receptor (TLR)-9, have demonstrated promising antitumor effects in some clinical trials; however, its toxicity and low efficacy as a systemic therapy has limited its therapeutic applications. In order to improve its therapeutic efficacy, we investigated the mechanisms of CpGinduced antitumor immunity in the context of CD8+ T cell responses. We show that IL-12 is required for the expansion of IFN-γ producing tumor-reactive CD8+ T cells capable of rejecting tumors. In addition, CpGs reduced PD-1 expression by effector CD8+ T cells via the IL-12 pathway. The combination of CpG and PD-1 blockade show a synergistic effect in generation of systemic antitumor immunity. Our studies define a critical role of IL-12 in CpG-induced antitumor immunity and provide a rationale for combined therapy with TLR agonists and immune checkpoint blockade in cancer treatment.

AB - CpG oligodeoxynucleotides, as a ligand of toll-like receptor (TLR)-9, have demonstrated promising antitumor effects in some clinical trials; however, its toxicity and low efficacy as a systemic therapy has limited its therapeutic applications. In order to improve its therapeutic efficacy, we investigated the mechanisms of CpGinduced antitumor immunity in the context of CD8+ T cell responses. We show that IL-12 is required for the expansion of IFN-γ producing tumor-reactive CD8+ T cells capable of rejecting tumors. In addition, CpGs reduced PD-1 expression by effector CD8+ T cells via the IL-12 pathway. The combination of CpG and PD-1 blockade show a synergistic effect in generation of systemic antitumor immunity. Our studies define a critical role of IL-12 in CpG-induced antitumor immunity and provide a rationale for combined therapy with TLR agonists and immune checkpoint blockade in cancer treatment.

KW - CpG ODN

KW - IL-12

KW - Immune checkpoints

KW - PD-1

KW - Tumor immunotherapy

UR - http://www.scopus.com/inward/record.url?scp=84994371723&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84994371723&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.11833

DO - 10.18632/oncotarget.11833

M3 - Article

C2 - 27602959

AN - SCOPUS:84994371723

VL - 7

SP - 70223

EP - 70231

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 43

ER -